These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15746578)

  • 1. In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment.
    Cabrespine A; Bay JO; Barthomeuf C; Curé H; Chollet P; Debiton E
    Anticancer Drugs; 2005 Apr; 16(4):417-22. PubMed ID: 15746578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro.
    Budman DR; Calabro A; Kreis W
    Anticancer Drugs; 2002 Nov; 13(10):1011-6. PubMed ID: 12439335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer.
    Cabrespine A; Guy L; Khenifar E; Curé H; Fleury J; Penault-Llorca F; Kwiatkowski F; Barthomeuf C; Chollet P; Bay JO
    Urology; 2006 Feb; 67(2):354-9. PubMed ID: 16442593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
    Sirotnak FM; She Y; Lee F; Chen J; Scher HI
    Clin Cancer Res; 2002 Dec; 8(12):3870-6. PubMed ID: 12473602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models.
    Xie X; Eberding A; Madera C; Fazli L; Jia W; Goldenberg L; Gleave M; Guns ES
    J Urol; 2006 May; 175(5):1926-31. PubMed ID: 16600800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines.
    Kreis W; Budman DR; Calabro A
    Br J Urol; 1997 Feb; 79(2):196-202. PubMed ID: 9052470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy.
    Schmidt U; Bilkenroth U; Linné C; Fuessel S; Kraemer K; Froehner M; Wirth MP; Meye A
    Int J Oncol; 2004 Jun; 24(6):1393-9. PubMed ID: 15138579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
    Hussain M; Petrylak D; Fisher E; Tangen C; Crawford D
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):55-60. PubMed ID: 10604271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer.
    Berry W; Friedland D; Fleagle J; Jackson D; Ilegbodu D; Boehm KA; Asmar L
    Clin Genitourin Cancer; 2006 Sep; 5(2):131-7. PubMed ID: 17026801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
    Stamelos VA; Robinson E; Redman CW; Richardson A
    Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial.
    Lin CC; Hsu CH; Hour TC; Cheng AL; Huang CY; Huang KH; Chen J; Pu YS
    Urol Oncol; 2007; 25(3):207-13. PubMed ID: 17483017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
    Miyake H; Chi KN; Gleave ME
    Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxazosin: a new cytotoxic agent for prostate cancer?
    Cal C; Uslu R; Gunaydin G; Ozyurt C; Omay SB
    BJU Int; 2000 Apr; 85(6):672-5. PubMed ID: 10759663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.
    Kelly WK; Curley T; Slovin S; Heller G; McCaffrey J; Bajorin D; Ciolino A; Regan K; Schwartz M; Kantoff P; George D; Oh W; Smith M; Kaufman D; Small EJ; Schwartz L; Larson S; Tong W; Scher H
    J Clin Oncol; 2001 Jan; 19(1):44-53. PubMed ID: 11134194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer.
    Waltmire CN; Alberts DS; Dorr RT
    Anticancer Drugs; 2001 Aug; 12(7):595-602. PubMed ID: 11487716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.
    Hudes GR; Obasaju C; Chapman A; Gallo J; McAleer C; Greenberg R
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):6-11. PubMed ID: 7597435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro.
    Budman DR; Calabro A; Wang LG; Liu XM; Stiel L; Adams LM; Kreis W
    Cancer Invest; 2000; 18(8):695-701. PubMed ID: 11107439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
    Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
    J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
    Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine.
    de Souza PL; Castillo M; Myers CE
    Br J Cancer; 1997; 75(11):1593-600. PubMed ID: 9184173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.